Notch1 - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector, 5µg of each construct provided
| Format | Lentiviral plasmids |
| Vector | pGFP-C-shLenti |
Products
Notch1 (Rat) - 3 unique 27mer siRNA duplexes - 2 nmol each
| Purity | HPLC purified |
| Number of Transfections | Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final conc. 10 nM). |
Notch1 (Mouse) - 3 unique 27mer siRNA duplexes - 2 nmol each
| Purity | HPLC purified |
| Number of Transfections | Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final conc. 10 nM). |
SR427840 is the updated version of SR423522.
Transient overexpression of NOTCH1 in HEK293T cells, FFPE control for IHC, ICC and ISH staining, 25 slides per pack
Notch1 - Rat, 4 unique 29mer shRNA constructs in retroviral untagged vector, 5µg of each construct provided
| Format | Retroviral plasmids |
| Vector | pRS |
Notch1 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector, 5µg of each construct provided
| Format | Lentiviral plasmids |
| Vector | pGFP-C-shLenti |
Anti-NOTCH1 rabbit polyclonal antibody
| Applications | IHC, WB |
| Reactivities | Human, Rat |
Anti-NOTCH1 rabbit polyclonal antibody
| Applications | IHC, WB |
| Reactivities | Human, Rat |
Anti-NOTCH1 Reference Antibody (brontictuzumab)
| Applications | Animal Model, ELISA, FACS, FN, Kinetics |
| Reactivities | Human, Mouse |
Anti-NOTCH1 Reference Antibody (Pfizer patent anti-Notch1)
| Applications | Animal Model, ELISA, FACS, FN, Kinetics |
| Reactivities | Human, Mouse |
Cleaved-Notch1 Rabbit polyclonal Antibody
| Applications | ELISA, IF, IHC, WB |
| Reactivities | Human, Mouse, Rat |
Recombinant Anti-Notch 1 (Clone E6)
| Applications | ELISA, IHC |
| Reactivities | Human, Mouse |
Rabbit polyclonal anti-NOTCH 1 antibody
| Applications | WB |
| Reactivities | Human, Mouse, Rat |
NOTCH1 mouse monoclonal antibody, clone mN1A, Purified
| Applications | FC, IHC, WB |
| Reactivities | Human, Mouse |
SM2297PS is a replacement of TA336494.
